Minerva Neurosciences (NERV) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 22, 2015
Document Entity Information [Abstract]
Entity Registrant Name	Minerva Neurosciences, Inc.
Entity Central Index Key	1598646
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,721,143
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$52,200,985	$18,545,702
Restricted cash	40,000	35,014
Prepaid expenses	503,317	756,979
Total current assets	52,744,302	19,337,695
Equipment, net	33,735	43,446
In-process research and development	34,200,000	34,200,000
Goodwill	14,869,399	14,869,399
Total assets	101,847,436	68,450,540
Current liabilities
Notes payable - current portion	158,263
Accounts payable	1,034,772	641,813
Accrued expenses and other current liabilities	1,771,439	1,645,258
Accrued collaborative expenses	1,461,342	1,222,420
Total current liabilities	4,425,816	3,509,491
Notes payable - noncurrent	9,546,861
Deferred taxes	13,433,760	13,433,760
Other noncurrent liabilities	5,129	7,694
Total liabilities	27,411,566	16,950,945
Commitments and contingencies
Stockholders’ equity
Preferred stock; $.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2015 and December 31, 2014, respectively
Common stock; $.0001 par value; 125,000,000 shares authorized; 24,721,143 and 18,439,482 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	2,472	1,844
Additional paid-in capital	155,257,875	126,228,981
Accumulated deficit	-80,824,477	-74,731,230
Total stockholders’ equity	74,435,870	51,499,595
Total liabilities and stockholders’ equity	$101,847,436	$68,450,540

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	24,721,143	18,439,482
Common stock, shares outstanding	24,721,143	18,439,482

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Expenses
Research and development	$3,961,205	$585,936
General and administrative	1,917,293	2,037,392
Total expenses	5,878,498	2,623,328
Loss from operations	-5,878,498	-2,623,328
Foreign exchange gains (losses)	15,960	-6,562
Interest (expense) income	-230,709	-308,528
Net loss	($6,093,247)	($2,938,418)
Net loss per share, basic and diluted	($0.31)	($0.43)
Weighted average shares outstanding, basic and diluted	19,416,629	6,902,910

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders' Equity (USD $)	Total	Private Placement	Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
	USD ($)		USD ($)	Private Placement	USD ($)	USD ($)
Balance at Dec. 31, 2014	$51,499,595		$1,844		$126,228,981	($74,731,230)
Balance (in shares) at Dec. 31, 2014			18,439,482
Issuance of common stock and warrants pursuant to a private placement, net of issuance costs of $2,473,189	28,526,810		628		28,526,182
Issuance of common stock and warrants pursuant to a private placement, net of issuance costs of $2,473,189 (in shares)				6,281,661
Issuance of warrant pursuant to loan agreement	166,344				166,344
Stock-based compensation	336,368				336,368
Net loss	-6,093,247					-6,093,247
Balances at Mar. 31, 2015	$74,435,870		$2,472		$155,257,875	($80,824,477)
Balance (in shares) at Mar. 31, 2015			24,721,143

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2015
Statement Of Stockholders Equity [Abstract]
Issuance cost	$2,473,189

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($6,093,247)	($2,938,418)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,711	270
Amortization of debt discount recorded as interest expense	67,124	274,312
Stock-based compensation expense	336,368	302,076
Unrealized foreign exchange gain		2,651
Change in fair value of derivative		-5,193
Changes in operating assets and liabilities
Prepaid expenses	253,662	-1,964
Accounts payable	254,529	1,187,152
Accrued expenses and other current liabilities	26,181	-60,424
Other Accrued Liabilities, collaborative expenses	238,922
Other noncurrent liabilities	-2,565
Net cash used in operating activities	-4,909,315	-1,239,538
Cash flows from investing activities:
Cash acquired in business combination		1,167,869
Restricted cash	-4,986
Net cash provided by investing activities	-4,986	1,167,869
Cash flows from financing activities:
Proceeds from loans	10,000,000	500,000
Costs paid in connection with loans	-195,656
Proceeds from sales of common stock in private placement	30,999,999
Costs paid in connection with private placement	-2,234,759
Public offering costs paid		-105,417
Net cash provided by financing activities	38,569,584	394,583
Net increase in cash and cash equivalents	33,655,283	322,914
Cash and cash equivalents
Beginning of period	18,545,702	1,818,317
End of period	52,200,985	2,141,231
Cash paid for interest	88,125
Incurred but unpaid private/public placement costs	238,430	1,075,818
Supplemental disclosure of noncash investing and financing activities
Common stock issued as consideration for business acquisition		16,541,834
Plus liabilities assumed:
Accrued expenses and other		321,417
ProteoSys milestone payable		681,600
Deferred tax liability		5,970,560
Less assets acquired:
Prepaid expenses		42,926
Equipment		28,204
In-process research and development		15,200,000
Goodwill		7,076,412
Cash acquired in business merger		1,167,869
Incurred but unpaid public offering costs		$1,075,818

Nature_of_Operations_and_Liqui

Nature of Operations and Liquidity	3 Months Ended
	Mar. 31, 2015
Nature Of Operations And Liquidity Disclosure [Abstract]
Nature of Operations and Liquidity	NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY
	Nature of Operations
	Minerva Neurosciences, Inc. (“Minerva” or the “Company”), formerly known as Cyrenaic Pharmaceuticals Inc. (“Cyrenaic”) was incorporated on April 23, 2007. On November 12, 2013, Sonkei Pharmaceuticals, Inc. (“Sonkei”), a biopharmaceutical company focused on the development of an experimental drug for the treatment of depression and an affiliated company through certain common ownership, was merged into Cyrenaic with Cyrenaic being the surviving company.  Subsequent to the merger, Cyrenaic changed its name to Minerva Neurosciences, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (“CNS”) diseases.
	On February 11, 2014, the Company acquired Mind-NRG (discussed further in Note 3 — Business Acquisition).  Mind-NRG is a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s disease. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate which underpins Mind-NRG’s lead product candidate, renamed MIN-301.
	On February 12, 2014, subject to the completion of an initial public offering (“IPO”), the Company entered into a co-development and license agreement (discussed further in Note 8 — Co-Development and License Agreement) pursuant to which the licensor granted the Company an exclusive license, in certain territories, under certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right, as an active ingredient, or MIN-202, for any use in humans. The license became effective on July 7, 2014 at the closing of the IPO and the payment of the $22.0 million license fee was made at that date.
	Going Concern
	The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of March 31, 2015, the Company has an accumulated deficit of approximately $80.8 million. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its business to date from proceeds from the sale of common stock, loans and convertible promissory notes.
	In January 2015, the Company entered into a loan and security agreement and drew down on $10.0 million in term loans.  In March 2015, the Company closed the sale of 6,281,661 shares of common stock and warrants to purchase an equal number of shares of common stock in a private placement resulting in net proceeds to the Company of $28.5 million after deducting placement fees and issuance costs. The Company believes that based on its operating plan, cash on hand at March 31, 2015 and the proceeds from the term loans and the private placement in March 2015 will be sufficient to fund the Company’s operations through the end of 2016.
	The Company will need to raise additional capital in order to continue to fund operations and fully fund its clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.
	The accompanying condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation
	The interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim reporting and the requirements of the Securities and Exchange Commission (“SEC”) in accordance with Regulation S-X, Rule 10-01. Under those rules, certain footnotes and financial information that are normally required for annual financial statements can be condensed or omitted. In the opinion of the Company’s management, the accompanying financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2015 and the results of operations and cash flows for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The consolidated balance sheet as of December 31, 2014 was derived from the audited annual financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited financial statements for the years ended December 31, 2014 and 2013 included in the Annual Report on Form 10-K.
	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG SA and Minerva Neurosciences Securities Corporation. Intercompany transactions have been eliminated.
	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of and demand for Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. We determine our expenses related to clinical studies based on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying condensed consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.5 million in accrued collaborative expenses as of March 31, 2015 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the three months ended March 31, 2015 and 2014.
	Stock-based compensation
	The Company recognizes compensation cost relating to stock-based payment transactions in operating results using a fair-value measurement method, in accordance with ASC Topic 718 Compensation-Stock Compensation. ASC-718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, expected forfeiture rate and expected life of the options.
	Grants to non-employees are accounted for in accordance with ASC Topic 505-50 Equity — Based Payments to Non-Employees. The date of expense recognition is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different and the fair value of each unvested award is adjusted at the end of each period for any change in fair value from the previous valuation until the award vests.
	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
	Business combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment annually at November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. There was no impairment of goodwill for the three months ended March 31, 2015 and 2014.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued but not yet adopted accounting pronouncements will not have a material impact on the consolidated financial position, consolidated results of operations, and consolidated cash flows, or do not apply to the Company.
	In April 2015, the FASB issued ASU 2015-03, which simplifies the presentation of debt issuance costs.  The Company has elected early adoption of this guidance and recorded its debt issuance costs associated with the Term Loans as a direct reduction to the face amount of the loans.

Business_Acquisition

Business Acquisition	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Acquisition	NOTE 3 — BUSINESS ACQUISITION
	On February 11, 2014, the Company acquired Mind-NRG, a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s disease. This transaction was accounted for as a business combination by the Company. The purchase price consisted of 1,481,583 shares of the Company’s common stock with an estimated fair value of $11.17 per share, or approximately $16.5 million. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate that underpins Mind-NRG’s lead product candidate, renamed MIN-301.
	The fair value of the Company’s common stock issued was determined based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company. The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Mind-NRG. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
	·	The fair value of current assets and liabilities approximated their book value.
	·	The Company measured the value of the acquired IPR&D using the income approach — multi period excess earnings method and assembled workforce using the cost approach (for contributory asset charge calculations). The multi-period excess earning method measures the present value of the future earnings expected to be generated during the remaining lives of the subject assets.
	·	The Company recorded a deferred tax liability for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax rate.
	The establishment of the fair value of the consideration for an acquisition, and the allocation to identifiable tangible and intangible assets and liabilities requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired and liabilities assumed are from estimates and assumptions based on data currently available.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. The goodwill recorded recognizes the value of the overall development program, both the current pre-clinical development program in process and the future clinical trial development strategy. Such goodwill is not deductible for tax purposes. The aggregate consideration of $16.5 million was allocated to assets acquired and liabilities assumed based on estimated fair values as follows:
	Cash	$	1,167,869
	Other assets		71,130
	Goodwill		7,076,412
	In-process research and development		15,200,000
	Deferred tax liability		(5,970,560	)
	Accrued expenses		(321,417	)
	ProteoSys milestone payable		(681,600	)
		$	16,541,834
	IPR&D, an indefinite-lived asset, has been included as an asset on the Company’s balance sheet until such time that: (i) a marketing approval to commercially sell the drug is received from a regulatory agency, in which case it will be amortized over its expected commercial life, or (ii) such time as the IPR&D is deemed to be impaired, in which case it will be expensed. The transaction is being treated as a stock purchase for income tax purposes and accordingly, the tax bases of Mind-NRG’s assets and liabilities are not adjusted for the effect of purchase accounting. In 2014, the Company corrected the deferred tax rate used to record a deferred tax liability at acquisition date by recording at $0.1 million reduction in deferred tax liability with a corresponding increase to goodwill.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables And Accruals [Abstract]
Accrued Expenses	NOTE 4 — ACCRUED EXPENSES
	Accrued expenses and other liabilities consist of the following:
		March 31, 2015		December 31, 2014
	Accrued bonus	$	546,761	$	327,960
	Research and development costs		498,094		415,595
	Accrued severance		318,750		636,033
	Professional fees		128,446		54,350
	Primomed research funding (1)		105,123		127,209
	Interest payable		58,750		-
	Accrued excise and franchise taxes		76,469		76,885
	Vacation pay		30,809		-
	Deferred rent, current		8,237		7,226
		$	1,771,439	$	1,645,258
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset certain costs under the MIN-301 development program.

Net_Loss_Per_Share_of_Common_S

Net Loss Per Share of Common Stock	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Share of Common Stock	NOTE 5 — NET LOSS PER SHARE OF COMMON STOCK
	Diluted loss per share is the same as basic loss per share for all periods presented as the effects of potentially dilutive issuances were anti-dilutive given the Company’s net loss. Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Three Months Ended
		March 31,
		2015			2014
	Net loss	$	(6,093,247	)	$	(2,938,418	)
	Weighted average shares of common stock outstanding		19,416,629			6,902,910
	Net loss per share of common stock – basic and diluted	$	(0.31	)	$	(0.43	)
	The following securities outstanding at March 31, 2015 and 2014 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		March 31,
		2015			2014
	Stock issued subject to recourse notes		-			926,604
	Common stock options		2,081,558			646,759
	Warrants		6,322,451			-

License_Agreements

License Agreements	3 Months Ended
	Mar. 31, 2015
License Agreement Disclosure [Abstract]
License Agreements	NOTE 6 — LICENSE AGREEMENTS
	The Company has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (“MTPC”) dated as of August 30, 2007, as amended (the “License Agreement”). Under the terms of the License Agreement, the Company acquired an exclusive license to the compound known as CYR-101 (subsequently renamed MIN-101), and other compounds with a similar structure and intended purpose and other data included within the valid claims of certain patents licensed to the Company under the License Agreement. The license is for world-wide rights, excluding certain Asian countries such as China, Japan, India and South Korea. The Company will pay a tiered royalty for net sales of product by it or any of its affiliates or sub-licensees containing the licensed compound equal to a percentage ranging from the high single digit to the low teens depending on net sales of products under the License Agreement. The initial $1.0 million licensing fee paid in 2007 was expensed as research and development expense, as was an additional payment of $0.5 million in 2008 upon the onset of a Phase IIa study. The Company made a $0.5 million extension payment in 2010 which was expensed as part of research and development expense. The Company was also required to make milestone payments upon the achievement of certain development and commercial milestones, potentially up to $57.5 million for MIN-101 and up to $59.5 million for additional products.
	In January 2014, the Company renegotiated the structure of the license for MIN-101 such that the Company is required to make milestone payments upon the achievement of one development milestone totaling $0.5 million and certain commercial milestones, which could total up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits.
	In connection with the merger of Sonkei in November 2013, the Company has a second license agreement with MTPC dated September 1, 2008, as amended. Under the terms of the agreement, the Company has an exclusive license to the compound known as SON-117 (subsequently renamed MIN-117) and other data included within the valid claims of certain patents licensed to the Company under the agreement. The license is for world-wide rights other than certain countries in Asia, including China, Japan, India and South Korea. Under the agreement, the Company will pay a tiered royalty for net sales of product by it or any of its affiliates or sub-licensees containing the licensed compound ranging from the high single digits to the low teens depending on net sales of products. Through the date of the agreement, as amended, the Company was required to make payments up to $57.5 million upon the achievement of certain commercial milestones.
	In January 2014, the Company renegotiated the structure of the license for MIN-117 such that the Company is required to make certain milestone payments upon the achievement of certain commercial milestones up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits. Under the terms of the amended agreement, the Company is required to initiate either a Phase IIa or Phase IIb study with the licensed compound in patients suffering major mood disorders where initiation is defined as first patient enrolled in the study by the end of April 2015. If the Company fails to achieve this milestone, the Company may elect to extend the timeline to achieve the milestone by one year increments by making an extension payment of $0.5 million. The number of extension payments which may be made is unlimited.
	The Company did not make any license payments under the agreements for the three months ended March 31, 2015 or 2014.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	NOTE 7 — DEBT
	Loan and Security Agreement
	On January 16, 2015, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB” and, together with Oxford, the “Lenders”), providing for term loans to the Company in an aggregate principal amount of up to $15 million, in two tranches.
	The Company drew down the initial term loans in the aggregate principal amount of $10 million (the “Term A Loans”), on January 16, 2015. The Term A Loans bear interest at a fixed rate of 7.05% per annum. On or prior to March 31, 2016, the Company may borrow additional term loans or Term B Loans and, together with the Term A Loans, (the “Term Loans”), in the aggregate principal amount up to $5 million, subject to the satisfaction of certain borrowing conditions, including its achievement of primary endpoints on its Phase IIa trials for its MIN-117 and MIN-202 programs. The Term B Loans will bear interest at a fixed rate per annum of the greater of (i) 7.05% or (ii) the sum of (a) the prime rate reported in The Wall Street Journal three (3) business days prior to the funding date of the Term B Loans, plus (b) 3.80%.
	The Company paid a facility fee of $75,000 for access to the Term Loans and will be required to pay a final payment of 4.45% (or, if the interest-only period is extended as described below, 5.10%) of the total amount borrowed, which has been included as a component of the debt discount and will be amortized to interest expense over the term of the loan.  The Term A Loans and debt discount are as follows:
		March 31, 2015
	Term A Loans	$	10,000,000
	Less: debt discount and financing costs		(294,876	)
	Less: current portion		(158,263	)
	Long-term portion	$	9,546,861
	For the three months ended March 31, 2015, the Company recognized interest expense of $0.2 million related to the Term A Loans, including $67 thousand related to the debt discount.
	Through February 1, 2016, the Company is obligated only to make monthly interest payments on the outstanding principal balance on the Term A Loans, followed by 30 months of equal principal and interest payments. If the Company raises at least $30.0 million in capital (including at least $20.0 million from the sale of equity securities) and completes the first dosing of its Phase I/II clinical trial for MIN-117 prior to December 31, 2015, the interest-only period will be extended an additional six months and the repayment period will be reduced by six months. The Company achieved the first milestone by raising approximately $31.0 million in gross proceeds in a private placement of common stock and warrants in March 2015.  The Term Loans mature on August 1, 2018. The Company may prepay all, but not less than all, of the loaned amount upon 30 days’ advance notice to the Lenders, provided that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the outstanding balance, if the loan is prepaid within 24 months of the funding date, (ii) 2% of the outstanding balance, if the loan is prepaid between 24 and 36 months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a “Prepayment Fee”).  The expected repayment of the $10.0 million Term A loan principal is as follows:
	2015		$	-
	2016			3,140,089
	2017			4,019,155
	2018			2,840,756
	Total Term A Loans		$	10,000,000
	The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, except that it may grant certain exclusive and non-exclusive licenses of its intellectual property as set forth in the Loan Agreement. In addition, the Company pledged all of its equity interests in Minerva Neurosciences Securities Corporation and 65% of its equity interests in Mind-NRG, SA as security for its obligations under the Loan Agreement.
	Upon the occurrence of certain events, including but not limited to the Company’s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, or the occurrence of a material adverse change, the Lenders will have the right, among other remedies, to declare all principal and interest immediately due and payable, and will have the right to receive the final payment fee and, if the payment of principal and interest is due prior to maturity, the applicable Prepayment Fee.
	Under the Loan Agreement, the Company agreed to issue the Lenders warrants to purchase shares of its common stock upon its draw of each tranche of the Term Loans. The aggregate number of shares of common stock issuable upon exercise of the warrants is equal to 2.25% of the amount drawn of such tranche, divided by the average closing price per share of the Company’s common stock reported on the NASDAQ Global Market for the 10 consecutive trading days prior to the applicable draw.  On January 16, 2015, upon the draw of the Term A Loans, the Company issued to the Lenders warrants to purchase 40,790 shares of common stock at a per share exercise price of $5.516. The warrants were immediately exercisable upon issuance, and other than in connection with certain mergers or acquisitions, will expire on the ten-year anniversary of the date of issuance.  The fair value of the warrants was estimated at $0.2 million using a Black-Scholes model and assuming: (i) expected volatility of 100.84%, (ii) risk free interest rate of 1.83%, (iii) an expected life of 10 years and (iv) no dividend payments.  The fair value of the warrants was included as a discount to the Term A Loans and also as a component of additional paid-in capital at March 31, 2015.

CoDevelopment_and_License_Agre

Co-Development and License Agreement	3 Months Ended
	Mar. 31, 2015
Co Development And License Agreement Disclosure [Abstract]
Co-Development and License Agreement	NOTE 8 — CO-DEVELOPMENT AND LICENSE AGREEMENT
	On February 12, 2014, the Company signed a co-development and license agreement with Janssen Pharmaceutica N.V. (“Janssen”) and Janssen Research & Development, LLC (“JJDC”), subject to the completion of an IPO and the payment of a $22.0 million license fee. Under the agreement, the licensor granted the Company an exclusive license, with the right to sublicense, in the European Union, Switzerland, Liechtenstein, Iceland and Norway, referred to as the Minerva Territory, under (i) certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right as an active ingredient and (ii) MIN-202 for any use in humans. In addition, upon regulatory approval in the Minerva Territory (and earlier if certain default events occur), the Company will have rights to manufacture MIN-202. The Company has granted to the licensor an exclusive license, with the right to sublicense, under all patent rights and know-how controlled by the Company related to MIN-202 to sell MIN-202 outside the Minerva Territory. In consideration of the licenses granted on July 7, 2014, the Company made a license fee payment of $22.0 million, which was included as a component of research and development expense in 2014. The Company will pay a quarterly royalty percentage in the high single digits on aggregate net sales for MIN-202 products sold by the Company, its affiliates and sublicensees in the European Union. The licensor will pay a quarterly royalty percentage to the Company in the high single digits on aggregate net sales for MIN-202 products sold by the licensor outside the European Union.  In accordance with the development agreement, the Company will pay 40% of MIN-202 development costs related to the joint development of any MIN-202 products. However, the Company’s share of aggregate development costs shall not exceed (i) $5.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase Ib clinical trials and animal toxicology studies, and (ii) $24.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase II clinical trials.  The licensor has a right to opt out at the end of certain development milestones, with the first milestone being the completion of a single day Phase I clinical trial in patients with MDD. Upon opt out, the licensor will not have to fund further development of MIN-202 and the Minerva Territory will be expanded to also include all of North America. The Company would then owe the licensor a reduced royalty in the mid-single digits for all sales in the Minerva Territory. The Company has the right to terminate the license following certain development milestones the first being completion of a certain Phase Ib clinical trial in patients with insomnia and certain toxicology studies in animals. If the Company terminates the license within 45 days of this milestone, the Company must pay a termination fee equal to $3.0 million. If the Company terminates the license at any time following the last development milestone involving a certain Phase IIb clinical trial, the Company will be entitled to a royalty in the mid-single digits from sales of MIN-202 by the licensor. The licensor may also terminate the agreement for the Company’s material breach or certain insolvency events, including if the Company is unable to fund its portion of the development costs.
	The Company included the $22.0 million license fee payment as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Payments between the Company and the licensor with respect to each party’s share of MIN-202 development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying consolidated statements of operations due to the joint risk-sharing nature of the activities. The Company has included $1.5 million and $1.2 million in accrued collaborative expenses as of March 31, 2015 and December 31, 2014, respectively.  The Company paid $1.2 million in February 2015 under this agreement.
	The Company entered into a common stock purchase agreement with an affiliate of the above mentioned licensor, dated as of February 12, 2014, pursuant to which, among other things, the affiliate agreed to purchase from the Company up to $26.0 million of common stock in a private placement concurrent with the closing of the IPO at a price equal to the IPO price. This investment was consummated simultaneously with the closing of an IPO in July 2014 with the purchase by the affiliate of 3,284,353 shares of common stock resulting in net proceeds to the Company of $19.7 million.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders' Equity	NOTE 9 — STOCKHOLDERS’ EQUITY
	Private Placement of Common Stock and Warrants
	On March 18, 2015, pursuant to a securities purchase agreement with certain accredited investors dated March 13, 2015, the Company sold in a private placement 6,281,661 shares of the Company’s common stock at a price per share of $4.81 and warrants to purchase up to an aggregate of 6,281,661 shares of common stock at a purchase price of $0.125 per warrant share, with an initial exercise price of $5.772 per share, resulting in gross proceeds of approximately $31.0 million.  The warrants will expire on March 18, 2017, two years after the date on which they were initially issued.  The Company incurred $2.5 million for placement agent fees and transaction costs which have been included as a component of additional paid-in capital, resulting in net proceeds of $28.5 million.
	In connection with the private placement, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”), dated March 13, 2015 with certain accredited investors. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the SEC a registration statement to register for resale the 6,281,661 shares of its common stock issued in the private placement and the 6,281,661 shares of its common stock issuable upon exercise of the warrants on or prior to May 2, 2015.  The Company filed a resale registration statement on April 30, 2015. If registration statements are not maintained effective, the Company could be subject to penalties of up to 10.0% of proceeds received in the private placement.
	Term Loan Warrants
	In connection with the Loan Agreement, the Company issued the Lenders warrants to purchase shares of its common stock upon its draw of each tranche of the Term Loans. The aggregate number of shares of common stock issuable upon exercise of the warrants is equal to 2.25% of the amount drawn of such tranche, divided by the average closing price per share of the Company’s common stock reported on the NASDAQ Global Market for the 10 consecutive trading days prior to the applicable draw.  Upon the draw of the Term A Loans, the Company issued the Lenders warrants to purchase 40,790 shares of common stock at a per share exercise price of $5.516. The warrants are immediately exercisable upon issuance, and other than in connection with certain mergers or acquisitions, will expire on the ten-year anniversary of the date of issuance.  The fair value of the warrants was estimated at $0.2 million using a Black-Scholes model and assuming: (i) expected volatility of 100.84%, (ii) risk free interest rate of 1.83%, (iii) an expected life of 10 years and (iv) no dividend payments.  The fair value of the warrants was included as a discount to the Term A Loans and also as a component of additional paid-in capital at March 31, 2015.

Stock_Option_Plan

Stock Option Plan	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Plan	NOTE 10 — STOCK OPTION PLAN
	The Company adopted the 2013 Equity Incentive Plan (the “Plan”) in December 2013, which provides for the issuance of options, stock appreciation rights, stock awards and stock units. On January 1, 2015, in accordance with the terms of the Plan, the total shares authorized for issuance under the plan increased by 737,579 to 4,281,333.  This increase represents 4% of the total shares outstanding calculated as of the end of the most recent fiscal year. The exercise price per share shall not be less than the fair value of the Company’s underlying common stock on the grant date and no option may have a term in excess of ten years. Stock option activity under the Plan is as follows:
						Weighted-Average
			Stock Options			Exercise Price
	Outstanding January 1, 2015			2,076,558		$	6.64
	Granted			25,000		$	5.05
	Forefeited			(20,000	)	$	6.26
	Outstanding March 31, 2015			2,081,558		$	6.63
	Exercisable March 31, 2015			1,308,685		$	6.84
	Available for future grant			2,199,775
	The Company uses the Black Scholes model to estimate the fair value of stock options granted.  For stock options granted on January 2, 2015 and February 2, 2015, the Company utilized the following assumptions:
		2-Jan-15	2-Feb-15
	Expected term (years)	6.25	5.5
	Risk free interest rate	1.80%	1.27%
	Volatility	109.86%	73.74%
	Dividend yield	0%	0%
	Grant date fair value per share of common stock	$5.13	$2.72
	The Company recognized stock-based compensation expense for the three months ended March 31, 2015 and 2014 of $0.3 million and $0.3 million, respectively.  The weighted average grant-date fair value of stock options outstanding on March 31, 2015 was $5.58 per share. Total unrecognized compensation costs related to non-vested awards at March 31, 2015 was approximately $3.6 million and is expected to be recognized within future operating results over a period of 2.93 years. At March 31, 2015, the weighted average contractual term of the options outstanding is approximately 9.2 years. The intrinsic value of outstanding stock options at March 31, 2015 was $9,900.
	The expected term of the employee-related options was estimated using the “simplified” method as defined by the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Company did not have any trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company has assumed no dividend yield for purposes of estimating the fair value of the options.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments	NOTE 11 — COMMITMENTS
	In September 2014, the Company entered into a lease agreement for 4,043 square feet of office space in Waltham, MA. The term of the lease is approximately 2 years, and the Company is required to make monthly rental payments commencing December 2014. Estimated annual rent payable under this operating lease is approximately $0.1 million per year in each of the two years.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 12 — RELATED PARTY TRANSACTIONS
	An investor previously provided accounting and other services to the Company, for the three months ended March 31, 2015 and 2014, the expense recognized in operating results in connection with these services was $0 and $25,000, respectively.
	For the three months ended March 31, 2015 and 2014, the Company retained the services of certain consultants who were also stockholders of the Company (see Note 9 – Stockholders’ Equity). The total expense recognized by the Company in connection with these consulting services was $0 and $199,438 for the three months ended March 31, 2015 and 2014, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 — SUBSEQUENT EVENTS
	In April 2015, the Company amended the diligence milestone obligation under the license agreement for MIN-117 to extend the deadline to initiate a Phase IIa or Phase IIb study with the licensed compound in patients suffering major mood disorders from April 30, 2015 to June 30, 2015. As consideration for such two-month extension, the Company agreed to pay $80,000 to MTPC. In the event the Company is unable to achieve such milestone by June 30, 2015, the Company may extend the milestone date to April 30, 2016 by making an additional extension payment of $0.5 million by June 30, 2015. The Company may make an unlimited number of annual extensions beyond April 30, 2016 if it is unable to achieve the milestone due to circumstances beyond its reasonable control by making an additional payment of $0.5 million for each extension before April 30 in each applicable year. All other terms of the license agreement for MIN-117 remain in effect.
	The Company amended the license agreement for MIN-117 to extend the April 30, 2015 milestone deadline because the Company plans to file an amendment to the protocol previously approved by the Latvian regulatory authorities for the double blinded placebo controlled Phase IIa study in patients with Major Depressive Disorder (“MDD”). The amendment will be filed to request an additional patient arm to evaluate a 2.5mg dose of MIN-117. If approved, the study is expected to include a total 80 patients, of which 20 would receive a 0.5mg dose of MIN-117, 20 would receive a 2.5mg dose of MIN-117, 20 would receive a 20mg dose of paroxetine and 20 would receive a placebo. The additional arm would explore the relative improvement in symptoms between the patients receiving 0.5mg and 2.5mg doses of MIN-117. The Company plans to begin enrollment for the Phase IIa study in the second quarter of 2015 and expects topline results of the Phase IIa study to be available in the first half of 2016.
	In April 2015, under the terms of the Plan, the Company granted 823,778 options to purchase common stock to employees with vesting terms over four years and a weighted average exercise price equal to the closing price of the stock on the date of grant of $5.18 per common share.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation
	The interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim reporting and the requirements of the Securities and Exchange Commission (“SEC”) in accordance with Regulation S-X, Rule 10-01. Under those rules, certain footnotes and financial information that are normally required for annual financial statements can be condensed or omitted. In the opinion of the Company’s management, the accompanying financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2015 and the results of operations and cash flows for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The consolidated balance sheet as of December 31, 2014 was derived from the audited annual financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited financial statements for the years ended December 31, 2014 and 2013 included in the Annual Report on Form 10-K.
Consolidation	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG SA and Minerva Neurosciences Securities Corporation. Intercompany transactions have been eliminated.
Significant Risks and Uncertainties	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of and demand for Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
Use of Estimates	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Costs	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. We determine our expenses related to clinical studies based on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying condensed consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.5 million in accrued collaborative expenses as of March 31, 2015 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the three months ended March 31, 2015 and 2014.
Stock-Based Compensation	Stock-based compensation
	The Company recognizes compensation cost relating to stock-based payment transactions in operating results using a fair-value measurement method, in accordance with ASC Topic 718 Compensation-Stock Compensation. ASC-718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, expected forfeiture rate and expected life of the options.
	Grants to non-employees are accounted for in accordance with ASC Topic 505-50 Equity — Based Payments to Non-Employees. The date of expense recognition is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different and the fair value of each unvested award is adjusted at the end of each period for any change in fair value from the previous valuation until the award vests.
Loss Per Share	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
Business Combinations	Business combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
Goodwill	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment annually at November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. There was no impairment of goodwill for the three months ended March 31, 2015 and 2014.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued but not yet adopted accounting pronouncements will not have a material impact on the consolidated financial position, consolidated results of operations, and consolidated cash flows, or do not apply to the Company.
	In April 2015, the FASB issued ASU 2015-03, which simplifies the presentation of debt issuance costs.  The Company has elected early adoption of this guidance and recorded its debt issuance costs associated with the Term Loans as a direct reduction to the face amount of the loans.

Business_Acquisition_Tables

Business Acquisition (Tables) (Mind-NRG)	3 Months Ended
	Mar. 31, 2015
Mind-NRG
Business Acquisition [Line Items]
Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed Based On Estimated Fair Value	The aggregate consideration of $16.5 million was allocated to assets acquired and liabilities assumed based on estimated fair values as follows:
	Cash	$	1,167,869
	Other assets		71,130
	Goodwill		7,076,412
	In-process research and development		15,200,000
	Deferred tax liability		(5,970,560	)
	Accrued expenses		(321,417	)
	ProteoSys milestone payable		(681,600	)
		$	16,541,834

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following:
		March 31, 2015		December 31, 2014
	Accrued bonus	$	546,761	$	327,960
	Research and development costs		498,094		415,595
	Accrued severance		318,750		636,033
	Professional fees		128,446		54,350
	Primomed research funding (1)		105,123		127,209
	Interest payable		58,750		-
	Accrued excise and franchise taxes		76,469		76,885
	Vacation pay		30,809		-
	Deferred rent, current		8,237		7,226
		$	1,771,439	$	1,645,258
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset certain costs under the MIN-301 development program.

Net_Loss_Per_Share_of_Common_S1

Net Loss Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Three Months Ended
		March 31,
		2015			2014
	Net loss	$	(6,093,247	)	$	(2,938,418	)
	Weighted average shares of common stock outstanding		19,416,629			6,902,910
	Net loss per share of common stock – basic and diluted	$	(0.31	)	$	(0.43	)
Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive	The following securities outstanding at March 31, 2015 and 2014 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		March 31,
		2015			2014
	Stock issued subject to recourse notes		-			926,604
	Common stock options		2,081,558			646,759
	Warrants		6,322,451			-

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Summary of Term A Loans and Debt Discount	The Term A Loans and debt discount are as follows:
		March 31, 2015
	Term A Loans	$	10,000,000
	Less: debt discount and financing costs		(294,876	)
	Less: current portion		(158,263	)
	Long-term portion	$	9,546,861
Expected Repayment of Term A loan principal	The expected repayment of the $10.0 million Term A loan principal is as follows:
	2015		$	-
	2016			3,140,089
	2017			4,019,155
	2018			2,840,756
	Total Term A Loans		$	10,000,000

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	Stock option activity under the Plan is as follows:
						Weighted-Average
			Stock Options			Exercise Price
	Outstanding January 1, 2015			2,076,558		$	6.64
	Granted			25,000		$	5.05
	Forefeited			(20,000	)	$	6.26
	Outstanding March 31, 2015			2,081,558		$	6.63
	Exercisable March 31, 2015			1,308,685		$	6.84
	Available for future grant			2,199,775
Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options	The Company uses the Black Scholes model to estimate the fair value of stock options granted.  For stock options granted on January 2, 2015 and February 2, 2015, the Company utilized the following assumptions:
		2-Jan-15	2-Feb-15
	Expected term (years)	6.25	5.5
	Risk free interest rate	1.80%	1.27%
	Volatility	109.86%	73.74%
	Dividend yield	0%	0%
	Grant date fair value per share of common stock	$5.13	$2.72

Recovered_Sheet1

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) (USD $)	1 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended
	Jan. 31, 2015	Mar. 18, 2015	Mar. 31, 2015	Jul. 07, 2014	Dec. 31, 2014	Feb. 11, 2014
Nature Of Operations And Liquidity [Line Items]
Accumulated deficit			-80,824,477		($74,731,230)
Loan and Security Agreement | Term Loan
Nature Of Operations And Liquidity [Line Items]
Amount drew dawn during period	10,000,000
Private Placement
Nature Of Operations And Liquidity [Line Items]
Shares of common stock issued		6,281,661
Shares of common stock to purchase by warrant		6,281,661
Common Stock | Private Placement
Nature Of Operations And Liquidity [Line Items]
Shares of common stock issued		6,281,661	6,281,661
Shares of common stock to purchase by warrant		6,281,661
Net proceeds from sale of common stock, net of underwriting discount		28,500,000
Mitsubishi | Co-development and License Agreement | MIN-202
Nature Of Operations And Liquidity [Line Items]
Payment of license fee				$22,000,000
Mind-NRG
Nature Of Operations And Liquidity [Line Items]
Share capital acquired (as a percent)						100.00%

Recovered_Sheet2

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 07, 2014	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Accrued collaborative expenses	$1,461,342			$1,222,420
Impairment of goodwill	0	0
In-Process Research and Development
Significant Accounting Policies [Line Items]
Asset impairment charges	0	0
Mitsubishi | Co-development and License Agreement | MIN-202
Significant Accounting Policies [Line Items]
Payment of license fee			22,000,000
Accrued collaborative expenses	$1,500,000			$1,200,000

BUSINESS_ACQUISITION_Additiona

BUSINESS ACQUISITION - Additional Information (Details) (Mind-NRG, USD $)	0 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 11, 2014	Dec. 31, 2014
Mind-NRG
Business Acquisition [Line Items]
Number of shares of common stock	1,481,583
Aggregate consideration	$16.50
Estimated fair value (in dollars per share)	$11.17
Share capital acquired (as a percent)	100.00%
(Increase) decrease in goodwill from reduction in deferred tax liability		$0.10

BUSINESS_ACQUISITION_Aggregate

BUSINESS ACQUISITION - Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed Based On Estimated Fair Value (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Feb. 11, 2014
Assets acquired and liabilities assumed based on estimated fair values
Goodwill	$14,869,399	$14,869,399
Mind-NRG
Assets acquired and liabilities assumed based on estimated fair values
Cash			1,167,869
Other assets			71,130
Goodwill			7,076,412
Deferred tax liability			-5,970,560
Accrued expenses			-321,417
Total			16,541,834
Mind-NRG | In-Process Research and Development
Assets acquired and liabilities assumed based on estimated fair values
In-process research and development			15,200,000
Mind-NRG | ProteoSys
Assets acquired and liabilities assumed based on estimated fair values
Milestone payable			($681,600)

ACCRUED_EXPENSES_Accrued_Expen

ACCRUED EXPENSES - Accrued Expenses and Other Liabilities (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014
Payables And Accruals [Abstract]
Accrued bonus	$546,761		$327,960
Research and development costs	498,094		415,595
Accrued severance	318,750		636,033
Professional fees	128,446		54,350
Primomed research funding	105,123	[1]	127,209	[1]
Interest payable	58,750
Accrued excise and franchise taxes	76,469		76,885
Vacation pay	30,809
Deferred rent, current	8,237		7,226
Accrued expenses and other liabilities	$1,771,439		$1,645,258
[1]	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset certain costs under the MIN-301 development program.

Recovered_Sheet3

NET LOSS PER SHARE OF COMMON STOCK - Computation of Basic and Diluted Loss Per Share (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss	($6,093,247)	($2,938,418)
Weighted average shares of common stock outstanding	19,416,629	6,902,910
Net loss per share, basic and diluted	($0.31)	($0.43)

Recovered_Sheet4

NET LOSS PER SHARE OF COMMON STOCK - Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Issued Subject to Recourse Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding		926,604
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	2,081,558	646,759
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	6,322,451

LICENSE_AGREEMENTS_Additional_

LICENSE AGREEMENTS - Additional Information (Details) (Mitsubishi, License Agreement, USD $)	1 Months Ended	4 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2007	Dec. 31, 2010	Dec. 31, 2008	Aug. 30, 2007	Sep. 01, 2008
	item
MIN-101
License Agreement
Payment of license fee		$1	$0.50	$0.50
Potential milestone payments upon achievement of milestone	0.5
Number of development milestones required	1
MIN-101 | Maximum
License Agreement
Potential milestone payments upon achievement of milestone	47.5				57.5
Additional Products | Maximum
License Agreement
Potential milestone payments upon achievement of milestone					59.5
MIN-117
License Agreement
Term of extension of the agreement	1 year
Potential extension payment	0.5
MIN-117 | Maximum
License Agreement
Potential milestone payments upon achievement of milestone	$47.50					$57.50

DEBT_Additional_Information_De

DEBT - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended	0 Months Ended
	Mar. 18, 2015	Mar. 31, 2015	Jan. 16, 2015	Mar. 31, 2016
Debt Instrument [Line Items]
Debt discount		$294,876
Proceeds from sales of common stock in private placement	31,000,000	30,999,999
Fair value of warrants estimated			200,000
Warrants
Debt Instrument [Line Items]
Expected stock price volatility (as a percent)			100.84%
Risk-free interest rate (as a percent)			1.83%
Expected life			10 years
Expected dividend			$0
Mind-NRG, SA
Debt Instrument [Line Items]
Percentage of equity interests		65.00%
Term Loan
Debt Instrument [Line Items]
Aggregate principal amount			15,000,000
Number of tranches			2
Facility fee payment			75,000
Final payment of term loan			4.45%
Extended interest of term loan			5.10%
Debt discount		67,000
Minimum capital requirement			30,000,000
Sale of equity securities			20,000,000
Extended interest period for debt instrument		6 months
Reduced repayment period for debt instrument		6 months
Proceeds from sales of common stock in private placement		31,000,000
Term loans maturity date		1-Aug-18
Advance notice period to the lenders		30 days
Term loan prepayment fee terms		(i) 3% of the outstanding balance, if the loan is prepaid within 24 months of the funding date, (ii) 2% of the outstanding balance, if the loan is prepaid between 24 and 36 months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a bPrepayment Feeb).
Aggregate number of shares of Common Stock issuable			2.25%
Consecutive trading days		10 days	10 days
Expiration anniversary date of issuance		10 years	10 years
Term Loan | 24 months
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance		3.00%
Term Loan | Between 24 and 36 months
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance		2.00%
Term Loan | Prepaid Thereafter
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance		1.00%
Term Loan | Term A Loans
Debt Instrument [Line Items]
Amount drew dawn during period			10,000,000
Interest rate (as a percent)			7.05%
Interest expense		200,000
Number of installments period		30 months
Shares of common stock to purchase by warrant			40,790
Common stock exercise price per share			$5.52
Term Loan | Term B Loans
Debt Instrument [Line Items]
Term loan, interest rate term		The Term B Loans will bear interest at a fixed rate per annum of the greater of (i) 7.05% or (ii) the sum of (a) the prime rate reported in The Wall Street Journal three (3) business days prior to the funding date of the Term B Loans, plus (b) 3.80%.
Term Loan | Term B Loans | Scenario, Forecast
Debt Instrument [Line Items]
Aggregate principal amount				$5,000,000
Interest rate (as a percent)				3.80%
Minimum percentage of interest rate on loan				7.05%

DEBT_Summary_of_Term_A_Loans_a

DEBT - Summary of Term A Loans and Debt Discount (Details) (USD $)	Mar. 31, 2015
Debt Disclosure [Abstract]
Term A Loans	$10,000,000
Less: debt discount and financing costs	-294,876
Less: current portion	-158,263
Long-term portion	$9,546,861

DEBT_Expected_Repayment_of_Ter

DEBT - Expected Repayment of Term A loan principal (Details) (USD $)	Mar. 31, 2015
Debt Disclosure [Abstract]
2016	$3,140,089
2017	4,019,155
2018	2,840,756
Total Term A Loans	$10,000,000

Recovered_Sheet5

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) (USD $)	0 Months Ended
	Feb. 28, 2015	Jul. 07, 2014	Feb. 12, 2014	Mar. 31, 2015	Dec. 31, 2014
Co-development and license agreement
Accrued collaborative expenses				$1,461,342	$1,222,420
Common Stock Purchase Agreement
Co-development and license agreement
Shares of common stock issued		3,284,353
Net proceeds from issuance of common stock		19,700,000
Common Stock Purchase Agreement | Maximum
Co-development and license agreement
Common stock agreed to be issued (in shares)			26,000,000
MIN-202 | Co-development and License Agreement | Phase Ib Clinical Trials | Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies			5,000,000
MIN-202 | Co-development and License Agreement | Phase II Clinical Trials | Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies			24,000,000
Mitsubishi | MIN-202 | Co-development and License Agreement
Co-development and license agreement
Payment of license fee		22,000,000
Percentage of development costs related to joint development of products			40.00%
Period within which agreement is terminated related to Phase Ib clinical trials milestone			45 days
Termination fee related to Phase Ib clinical trial milestone			3,000,000
Accrued collaborative expenses				1,500,000	1,200,000
Payment of development costs	$1,200,000

STOCKHOLDERS_EQUITY_Private_Pl

STOCKHOLDERS' EQUITY - Private Placement of Common Stock and Warrants - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended
	Mar. 18, 2015	Mar. 31, 2015
Stockholders Equity [Line Items]
Gross proceeds from issuance of common stock and warrants	$31,000,000	$30,999,999
Issuance cost		2,473,189
Private Placement
Stockholders Equity [Line Items]
Shares of common stock issued	6,281,661
Shares of common stock to purchase by warrant	6,281,661
Sale of common stock, price per share	$4.81
Warrants price per share	$0.13
Initial exercise price of warrants	$5.77
Warrants expiration date	18-Mar-17
Issuance cost	2,473,189
Net proceeds from sale of common stock	$28,500,000
Registration rights agreement date		13-Mar-15
Registration rights agreement term		Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the SEC a registration statement to register for resale the 6,281,661 shares of its common stock issued in the private placement and the 6,281,661 shares of its common stock issuable upon exercise of the warrants on or prior to May 2, 2015.
Penalty percentage for not meeting the registration agreement		10.00%

STOCKHOLDERS_EQUITY_Term_Loan_

STOCKHOLDERS' EQUITY - Term Loan Warrants - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Jan. 16, 2015	Mar. 31, 2015
Stockholders Equity [Line Items]
Fair value of warrants estimated	0.2
Warrants
Stockholders Equity [Line Items]
Expected stock price volatility (as a percent)	100.84%
Risk-free interest rate (as a percent)	1.83%
Expected life	10 years
Expected dividend rate (as a percent)	0.00%
Term Loan
Stockholders Equity [Line Items]
Aggregate number of shares of Common Stock issuable	2.25%
Consecutive trading days	10 days	10 days
Expiration anniversary date of issuance	10 years	10 years
Term Loan | Term A Loans
Stockholders Equity [Line Items]
Shares of common stock to purchase by warrant	40,790
Initial exercise price of warrants	5.516

STOCK_OPTION_PLAN_Additional_I

STOCK OPTION PLAN - Additional Information (Details) (USD $)	0 Months Ended		3 Months Ended
	Feb. 02, 2015	Jan. 02, 2015	Mar. 31, 2015	Mar. 31, 2014	Jan. 01, 2015
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Fair value of common stock on grant date (in dollars per share)	$2.72	$5.13
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Additional disclosure
Stock based compensation expense			$300,000	$300,000
Total unrecognized compensation costs related to non-vested awards (in dollars)			3,600,000
Period over which unrecognized compensation costs related to non-vested awards is expected to be recognized			2 years 11 months 5 days
Weighted average contractual term of the options outstanding			9 years 2 months 12 days
Intrinsic value of outstanding stock options (in dollars)			$9,900
2013 Equity Incentive Plan
Stock Option Plan
Increase in number of shares authorized for issuance		737,579
Shares authorized for issuance under the plan					4,281,333
Additional shares authorized for issuance under the plan as percentage of total shares outstanding		4.00%
2013 Equity Incentive Plan | Stock Option
Stock Option Plan
Term of share-based award		10 years
Amended And Restated Equity Incentive Plan
Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model
Fair value of common stock on grant date (in dollars per share)			$5.58

STOCK_OPTION_PLAN_Stock_Option

STOCK OPTION PLAN - Stock Option Activity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Stock Options
Outstanding at the beginning of period (in shares)	2,076,558
Granted (in shares)	25,000
Forfeited (in shares)	-20,000
Outstanding at the end of the period (in shares)	2,081,558
Exercisable at the end of the period (in shares)	1,308,685
Available for future grant (in shares)	2,199,775
Weighted-Average Exercise Price
Outstanding at the beginning of period (in dollars per share)	$6.64
Granted (in dollars per share)	$5.05
Forfeited (in dollars per share)	$6.26
Outstanding at the end of the period (in dollars per share)	$6.63
Exercisable at the end of the period (in dollars per share)	$6.84

STOCK_OPTION_PLAN_Summary_of_A

STOCK OPTION PLAN - Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options (Details) (USD $)	0 Months Ended		3 Months Ended
	Feb. 02, 2015	Jan. 02, 2015	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (years)	5 years 6 months	6 years 3 months
Risk free interest rate	1.27%	1.80%
Volatility	73.74%	109.86%
Dividend yield	0.00%	0.00%	0.00%
Grant date fair value per share of common stock	$2.72	$5.13

COMMITMENTS_Additional_Informa

COMMITMENTS - Additional Information (Details) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
	sqft
Commitments And Contingencies Disclosure [Abstract]
Area of office space	4,043
Estimated annual rent payable	$0.10
Lease term	2 years

RELATED_PARTY_TRANSACTIONS_Add

RELATED PARTY TRANSACTIONS - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Investor
Related Party Transaction [Line Items]
Related party expenses	$0	$25,000
Certain stockholders
Related Party Transaction [Line Items]
Related party expenses	$0	$199,438

SUBSEQUENT_EVENTS_Additional_I

SUBSEQUENT EVENTS -Additional Information (Details) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Subsequent Event [Line Items]
Stock options weighted average exercise price	$5.05
Scenario, Forecast | MIN-117 | License Agreement | Mitsubishi
Subsequent Event [Line Items]
Potential extension payment	$500,000
Additional payment for each extension	500,000
Subsequent event
Subsequent Event [Line Items]
Stock options granted		823,778
Stock options weighted average exercise price		$5.18
Vesting period		4 years
Subsequent event | MIN-117 | License Agreement | Mitsubishi
Subsequent Event [Line Items]
Extension of milestone payment		$80,000